Teva Pharmaceutical Industries Limited (NYSE:TEVA) ranks among billionaire Stanley Druckenmiller’s 10 best stock picks. Truist Securities boosted Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s ...

Investors might want to bet on Teva Pharmaceutical Industries Ltd. (TEVA), as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is among the 7 Cheap Pharmaceutical Stocks to Buy According to Hedge Funds ...

The latest update to Teva Pharmaceutical Industries' narrative centers on a modestly higher fair value estimate, now at US$37.95 per share compared with the prior US$36.77, reflecting how recent ...

Teva Pharmaceutical Indus (NYSE: TEVA) underwent analysis by 13 analysts in the last quarter, revealing a spectrum of ...

Teva Pharmaceutical Industries Limited’s TEVA stock has risen 12.9% in a month. Teva’s stock mainly gained after it announced first-quarter 2025 results on May 7. Teva’s first-quarter results were ...

Teva's stock has risen 105% in two years, outperforming the S&P 500, but it is no longer a bargain at $17.50 per share. The company's focus on debt reduction has been successful, with net debt falling ...

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) stock is trading higher on Wednesday after the company’s first-quarter 2025 financial results. Here are the details. Teva reported revenue of $3.89 ...

Corcept Therapeutics lost its patent-infringement battle with Teva Pharmaceutical Industries, exposing Corcept to more competition from generic drugs. The ruling from the U.S. Court of Appeals for the ...

Teva Pharmaceutical Industries Limited’s TEVA stock has been trading above its 50-day and 200-day simple moving averages (SMAs) since the end of October. It achieved the golden cross in mid-September.